# OnCo record idea-tnbc-ctdna-guided-adjuvant-decisions (idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/ideas/idea-tnbc-ctdna-guided-adjuvant-decisions/>
  a schema:CreativeWork ;
  onco:kind "idea" ;
  schema:identifier "idea-tnbc-ctdna-guided-adjuvant-decisions" ;
  schema:name "ctDNA-guided adjuvant decisions after residual disease: escalate the positive, spare the negative"@en ;
  schema:description "After pre-surgery chemotherapy leaves tumour behind, a blood test for tumour DNA triples the risk of distant relapse when positive. The one trial that acted on it found the DNA usually appeared too late. A trial that tests at surgery with a tumour-informed assay, escalates positives to an antibody-drug conjugate and observes negatives has not been run."@en ;
  schema:url <https://onco.cc/ideas/idea-tnbc-ctdna-guided-adjuvant-decisions/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://europepmc.org/article/MED/32644110>, <https://europepmc.org/article/MED/36423745>, <https://clinicaltrials.gov/study/NCT05633654>, <https://clinicaltrials.gov/study/NCT05629585> ;
  onco:tag "tnbc-evidence" ;
  onco:related <https://onco.cc/roadmaps/ctdna-tests/> ;
  onco:cancers <https://onco.cc/cancers/tnbc/> ;
  onco:technologies <https://onco.cc/technologies/liquid-biopsy/>, <https://onco.cc/technologies/mrd-testing/>, <https://onco.cc/technologies/adc/> ;
  onco:drugs <https://onco.cc/drugs/sacituzumab-govitecan/>, <https://onco.cc/drugs/datopotamab-deruxtecan/>, <https://onco.cc/drugs/capecitabine/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/signatera/> ;
  onco:terms <https://onco.cc/terms/ctdna/>, <https://onco.cc/terms/mrd/>, <https://onco.cc/terms/rcb/>, <https://onco.cc/terms/neoadjuvant-adjuvant/> ;
  onco:trials <https://onco.cc/trials/ascent-05/>, <https://onco.cc/trials/tropion-breast03/>, <https://onco.cc/trials/keynote-522/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-dormancy-mrd/>, <https://onco.cc/bottlenecks/b-biomarker-validation/>, <https://onco.cc/bottlenecks/b-trial-design/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-radovich-ctdna-ctc-bre12-158-jama-oncol-2020/>, <https://onco.cc/key-papers/paper-turner-c-trak-tn-ctdna-pembrolizumab-ann-oncol-2023/>, <https://onco.cc/key-papers/paper-symmans-rcb-long-term-prognosis-subtype-jco-2017/>, <https://onco.cc/key-papers/paper-yau-rcb-pooled-analysis-5161-lancet-oncol-2022/>, <https://onco.cc/key-papers/paper-create-x-adjuvant-capecitabine-nejm-2017/> .